Hepatic Adenoma Under 5 cm in Women: What to Do When Initial Management Has Not Achieved Stability

Clinical scenario

This protocol is for women with a hepatic cell adenoma (HCA) measuring under 5 cm. In this population, asymptomatic lesions are eligible for initial conservative management, with contrast-enhanced MRI used to monitor size and behaviour over time.

When first-line management has not worked

The initial approach — discontinuation of exogenous hormonal therapy, combined with weight loss where applicable in overweight or obese individuals — aims for stability or regression of the adenoma on contrast-enhanced MRI at six months. This protocol applies when that outcome has not been achieved: the adenoma has not stabilised or regressed on follow-up imaging.

Next-step approach (partial overview)

When conservative management does not produce the expected response, this protocol outlines a definitive surgical approach to the adenoma. The full structured regimen — including the specific criteria, clinical decision points, and sequencing — is available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.14309/ajg.0000000000002857

Females with asymptomatic HCAs diagnosed at <5 cm in size can be monitored and initially managed conservatively unless imaging prompts concerns for b-catenin mutated subtype.

In women with hepatic adenomas <5 cm, we suggest discontinuation of exogenous hormones and advise weight loss, if applicable, for overweight or obese individuals (conditional recommendation, very low level of evidence).

During surveillance, if there is growth of the lesion, suggested as ≥20% as extrapolated from RECIST criteria for malignant liver tumors, resection or definitive treatment should be considered.

Cases where biopsy is positive for b-catenin mutation in exon 3 or that have transformed to HCC should proceed with resection.

View source ↗